Nab-paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice

• Verfasst von: Aigner, Julia [VerfasserIn]
• Verfasst von: Marmé, Frederik [VerfasserIn]
• Verfasst von: Smetanay, Katharina [VerfasserIn]
• Verfasst von: Schütz, Florian [VerfasserIn]
• Verfasst von: Jäger, Dirk [VerfasserIn]
• Verfasst von: Schneeweiss, Andreas [VerfasserIn]
• Titel: Nab-paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice
• Verf.angabe: Julia Aigner, Frederik Marmé, Katharina Smetanay, Florian Schuetz, Dirk Jaeger and Andreas Schneeweiss
• E-Jahr: 2013
• Jahr: August 2013
• Umfang: 7 S.
• Teil: volume:33
• Teil: year:2013
• Teil: number:8
• Teil: month:08
• Teil: pages:3407-3413
• Teil: extent:7
• Fussnoten: Gesehen am 07.05.2021
• Titel Quelle: Enthalten in: Anticancer research
• Ort Quelle: Attiki, 2004
• Jahr Quelle: 2013
• Band/Heft Quelle: 33(2013), 8 vom: Aug., Seite 3407-3413
• ISSN Quelle: 1791-7530
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: chemotherapy
• Sach-SW: Metastatic breast cancer
• Sach-SW: nab-paclitaxel
• K10plus-PPN: 1757479465

Abstract

Aim: To compare treatment results with use of nab-paclitaxel in routine clinical practice with data obtained from clinical trials. Patients and Methods: A retrospective chart review of all 36 patients with metastatic breast cancer treated with nab-paclitaxel was performed. Nab-paclitaxel was given weekly and usually started at 150 mg/m2. Results: Thirteen (36.1%) patients received nab-paclitaxel as first-line, seven (19.4%) as second-line and 16 as third- or further line treatment. Overall, the response rate was 9.7%, disease control rate 64.5%, median progression-free survival 7.5 months and median overall survival 14.2 months. The most frequent non-hematological toxicities of grade 3 or more were fatigue (27.8%), dyspnea, rash and arthalgia (all 5.6%). Six (16.7%) patients developed peripheral neuropathy of grade 2 or more. Incidence of neutropenia grade 3 or more was 41.7% with no case of febrile neutropenia. Conclusion: According to our experience, weekly nab-paclitaxel is effective and tolerable, with results at least comparable to those from the prospective clinical trials.